Podcasts about Johns Hopkins

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss several states and the governor of Pennsylvania suing HHS over changes in the childhood vaccination schedule, the vaccine derived type 2 poliovirus outbreak in Pakistan and implications for the global withdrawal of the oral poliovirus vaccine, and the outbreak of Candida, then Dr. Griffin deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, when to use steroids for treating influenza, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode States vs RFK Jr and Bhattacharya: changes to the childhood vaccine schedule (Office of the Attorney General, California) Surgeon General Nominee Sidesteps Questions on Vaccines at Senate Hearing (NY Times) Unqualified failure in polio vaccine policy left thousands of kids paralyzed (Science) Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021 (CID) Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication (CID) Wastewater for Candida auris: Wastewater (WasterWater Scan) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah Measles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) COVID-19 vaccination status during pregnancy and preeclampsia risk: the pandemic-era cohort of the INTERCOVID consortium (eClinical Medicine) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis(Scientific Reports) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1300 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

There is a palpable mix of excitement and anxiety about the latest impending wave of Artificial Intelligence. AI tools are being developed that will fundamentally impact our jobs, our relationships, our access to knowledge and creativity, our children's lives, and our planet. But for an industry like healthcare — where fax machines and pagers are common, where people struggle to find affordable care or adequate resources, and nurses are leaving the profession due to administrative burdens and moral distress — can AI be an answer?  In this two-part feature of our AI in Play series, where we explore AI's role in transforming healthcare, host Oriana Beaudet, Vice President of Innovation at the American Nurses Association, Credentialing Center, and Foundation, talks with a nurse and a clinician helping to shape the future of AI in healthcare for one of the largest technology companies in the world.   Episode 130 features nurse Mary Varghese-Presti, Corporate VP and COO of Microsoft Health and Life Sciences, whose team built Dragon Copilot, the first commercially available ambient AI solution purpose-built for nursing workflows. We learn how Microsoft co-designed this tool directly with staff nurses, nurse managers, and nurse executives across more than 10 health systems,  and why that collaboration is essential. We'll learn about Microsoft's vision for a three-stage AI future, from co-pilots to agents to a true hybrid workforce, and what it would mean for nurses to have the ability to delegate tasks the way physicians have long been able to do. Finally, we hear the deeply personal story behind Mary's mission,  from growing up in an immigrant household surrounded by nurse "aunties," to advocating for a voiceless patient at 4 am as a young nurse at Johns Hopkins, to now leading the technology that she believes will restore humanity and dignity to the very profession that shaped her.  Episode 131 features Dominic King, former surgeon and VP of Health at Microsoft AI, where his team builds and scales consumer health tools that see more than 50 million health-related sessions a day. In this conversation, we learn about Microsoft's partnership with Harvard Medical School and how it's working to ensure that the billions of health questions people ask AI every day are met with credible, clinically sound information. We also hear how he thinks about patient safety and trust in AI, and we'll get his candid take on what AI cannot replace, why clinicians must be central to scaling these tools beyond the pilot stage, and how he believes technology is the single biggest lever for making health systems sustainable in the face of growing global demand.      For more information on the podcast bundles, visit ANA's Innovation Website at https://www.nursingworld.org/practice-policy/innovation/education.    Have questions or feedback for the SEE YOU NOW team?  Future episode ideas? Contact us at hello@seeyounowpodcast.com.       

There is a palpable mix of excitement and anxiety about the latest impending wave of Artificial Intelligence. AI tools are being developed that will fundamentally impact our jobs, our relationships, our access to knowledge and creativity, our children's lives, and our planet. But for an industry like healthcare — where fax machines and pagers are common, where people struggle to find affordable care or adequate resources, and nurses are leaving the profession due to administrative burdens and moral distress — can AI be an answer?  In this two-part feature of our AI in Play series, where we explore AI's role in transforming healthcare, host Oriana Beaudet, Vice President of Innovation at the American Nurses Association, Credentialing Center, and Foundation, talks with a nurse and a clinician helping to shape the future of AI in healthcare for one of the largest technology companies in the world.   Episode 130 features nurse Mary Varghese-Presti, Corporate VP and COO of Microsoft Health and Life Sciences, whose team built Dragon Copilot, the first commercially available ambient AI solution purpose-built for nursing workflows. We learn how Microsoft co-designed this tool directly with staff nurses, nurse managers, and nurse executives across more than 10 health systems,  and why that collaboration is essential. We'll learn about Microsoft's vision for a three-stage AI future, from co-pilots to agents to a true hybrid workforce, and what it would mean for nurses to have the ability to delegate tasks the way physicians have long been able to do. Finally, we hear the deeply personal story behind Mary's mission,  from growing up in an immigrant household surrounded by nurse "aunties," to advocating for a voiceless patient at 4 am as a young nurse at Johns Hopkins, to now leading the technology that she believes will restore humanity and dignity to the very profession that shaped her.  Episode 131 features Dominic King, former surgeon and VP of Health at Microsoft AI, where his team builds and scales consumer health tools that see more than 50 million health-related sessions a day. In this conversation, we learn about Microsoft's partnership with Harvard Medical School and how it's working to ensure that the billions of health questions people ask AI every day are met with credible, clinically sound information. We also hear how he thinks about patient safety and trust in AI, and we'll get his candid take on what AI cannot replace, why clinicians must be central to scaling these tools beyond the pilot stage, and how he believes technology is the single biggest lever for making health systems sustainable in the face of growing global demand.    For more information on the podcast bundles, visit ANA's Innovation Website at https://www.nursingworld.org/practice-policy/innovation/education.    Have questions or feedback for the SEE YOU NOW team?  Future episode ideas? Contact us at hello@seeyounowpodcast.com. 

Broadcast from KSQD, Santa Cruz on 2-26-2026: Dr. Dawn opens with an urgent measles advisory, noting the virus has an R-value of 15 compared to COVID's peak of 5, with South Carolina reporting over 1,000 cases. She recommends those who received only one MMR shot—particularly people now in their 60s—get an immune titer blood test, as protection declines after 40-50 years. Measles can cause "immune amnesia" destroying immunity to other pathogens, and rarely leads to fatal subacute sclerosing panencephalitis years later. Dr. Dawn criticizes Quest Labs' cholesterol reporting, which flags average levels as "moderate risk" with alarming red H markers even when values fall within their own stated normal ranges. She explains this creates unnecessary panic and pushes patients toward statins based on outdated 2008-2012 guidelines, when cardiology has since recognized that cholesterol can be too low. An emailer asks how an EKG can detect a past heart attack from "jagged lines." Dr. Dawn explains that each spike represents electrical signals moving toward or away from electrode pads, and a 12-lead EKG views the heart from multiple angles—smaller-than-expected spikes in specific leads indicate dead or damaged heart muscle. She urges everyone to learn CPR and AED use, which more than doubles survival chances. An emailer reports that food tastes strong on the first bite but becomes tasteless thereafter. Dr. Dawn identifies numerous medications causing taste changes including calcium channel blockers, beta blockers, statins, diuretics, and even acetaminophen. She also highlights zinc—both deficiency and toxicity above 40mg daily can impair taste, noting a zinc nasal spray was pulled from market after causing smell loss. An emailer asks about Prenuvo full-body MRI scans costing $499-1,000. Dr. Dawn cautions that while Prenuvo found 22 cancers in 1,000 people scanned, 1 in 20 scans requires follow-up biopsy and more than half are false positives—leading to stress, expense, and potential complications from unnecessary procedures. An emailer asks about seed oils after reading a Johns Hopkins article defending them. Dr. Dawn distinguishes fruit oils (olive, avocado) from industrially-extracted seed oils requiring hexane solvent, a neurotoxin that may leave residues despite claims of evaporation. She cites a BMJ study showing coconut oil raised HDL (good cholesterol) while matching olive oil's LDL impact, and recommends cold-pressed oils while avoiding hexane-extracted products, especially for infants.

This week, Scotty Wazz looks at some of the season's ending for the Maryland college squads, while Stevenson and Navy's Men, as well as Navy and Maryland's Women prep for their playoffs this weekend. Also, Johns Hopkins wins one of the ACCHL D3 Titles. 

IMS Radio – Be The Best Podcast – Season 1, Episode 3 Current Maryland midfielders Zach Whittier and Aiden Aitken join the podcast to talk about their recruitment to Maryland, who they see as unsung teammates, and their favorite off-field memories about the team. We recap last week's 13-12 loss to Princeton, as well as Harvard's win over Syracuse, Navy's win over Penn State, and Johns Hopkins' loss to North Carolina. We then preview Maryland's upcoming home game against second-ranked Notre Dame.  Finally, we close out with our picks for the upcoming weekend. The Ivy League and ACC do their crossover weekend with Penn hosting top-ranked North Carolina and Princeton hosting Syracuse on Friday. On Sunday, the opponents flip with Syracuse heading down to Penn and North Carolina heading up to Princeton. We also discuss Richmond's visit to Cornell and Ohio State's trip to Georgetown. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Our Titan of Science this week is leading light in the field of malaria, Jane Carlton. The first to sequence the genome of malaria parasite Plasmodium vivax, she also helped sequence the deadlier Plasmodium falciparum. Jane tells Chris Smith the ins and outs of malaria, her journey to become Director of the Malaria Research Institute at Johns Hopkins, and how stealing her brother's genetics textbook when she was just 8 years old led her to where she is today... Like this podcast? Please help us by supporting the Naked Scientists

Gang members in Mexico are retaliating against the killing of most-wanted cartel boss "El Mencho," torching buses and businesses, clashing with security forces, and setting hundreds of blockades across 20 Mexican states. Mexico's President Claudia Sheinbaum told the country this morning that peace and security is "being maintained" and stressed the key role Mexico's military played in the operation. Mexican scholar Viri Rios joins the show from Mexico City.  Also on today's show: CNN International Correspondent Max Foster; Yale Law School professor Natasha Sarin; Johns Hopkins professor Vali Nasr; legendary musician Wynton Marsalis    Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Hunt Priest, founder of Ligare, about Christianity, mysticism, and the ethical integration of psychedelic experience within spiritual life. Find full show notes and links here: https://thethirdwave.co/podcast/episode-344/?ref=278  They discuss Hunt's participation in a 2016 Johns Hopkins psilocybin study for clergy, Christianity's long history of mystical experience, and how non-ordinary states can be held within ethical and communal containers. The conversation also explores legality versus ethics, justice and institutional risk, and how psychedelics relate to prayer, meditation, and service within a broader spiritual life. Hunt Priest is a Christian minister and founder of Ligare, a nonprofit exploring the relationship between Christianity and psychedelics. Formerly an Episcopal priest, he works at the intersection of spiritual formation, ethics, and community-based integration of mystical experience. Highlights: Johns Hopkins clergy study Christian mysticism and non-ordinary states Psychedelics as catalysts for spiritual practice Legal versus ethical tensions Institutional risk and grace Episode Links: Ligare Hunt on Substack Episode Sponsors: The Practitioner Certification Program by Third Wave's Psychedelic Coaching Institute. The Microdosing Practitioner Certification at Psychedelic Coaching Institute. Golden Rule - Get a lifetime discount of 10% with code THIRDWAVE at checkout Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization. Third Wave occasionally partners with or shares information about other people, companies, and/or providers. While we work hard to only share information about ethical and responsible third parties, we can't and don't control the behavior of, products and services offered by, or the statements made by people, companies, or providers other than Third Wave. Accordingly, we encourage you to research for yourself, and consult a medical, legal, or financial professional before making decisions in those areas. Third Wave isn't responsible for the statements, conduct, services, or products of third parties. If we share a coupon code, we may receive a commission from sales arising from customers who use our coupon code. No one is required to use our coupon codes.

If you're like many people you'd rather not develop dementia, so a new study demonstrating the benefits of a computer based intervention called cognitive speed training may interest you. Marilyn Albert, study author and Alzheimer's disease expert at Johns Hopkins, … If you're looking to preserve brain health doing cognitive speed training may be best, Elizabeth Tracey reports Read More »

Hur mår egentligen Donald Trump? Flera läkare menar att presidenten uppvisar tecken på begynnande demens. En av dem är John Gartner, tidigare professor på anrika Johns Hopkins-universitet. Att Trump ibland verkar vara förvirrad, ha svamlande tal och humörsvängningar menar han kan förklaras av en demenssjukdom. Trump och Vita Huset själva, säger att han är fullt frisk och vid god hälsa. Samtidigt har USA genom historien haft en tendens att spela ner presidenters olika åkommor eller hälsoproblem. Så vad ska man tro på? Hur mår egentligen USA:s snart 80-årige president? Gäst: Andreas Utterström, USA-kännare Programledare och producent: Love Isakson Svensén Klipp från: The Independent, New York Post Kontakt: podcast@aftonbladet.se Ansvarig utgivare: Lotta Folcker

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss reversal of last week's no review decision on a flu mRNA vaccine by Vinjay Prasad, appointment of Jay Bhattacharya as CDC director, no experience required, and already detectable reduction in hepatitis B virus vaccination rates, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, the consequences of measles infection on immune amnesia (shout out to Immune 26), long COVID treatment center, where to go for answers to your long COVID questions, long COVID effect on fertility and type 2 diabetes and contacting your federal government representative to stop the assault on science and biomedical research.   Click arrow to play Download TWiV 1298 (26 MB .mp3, 43 min) Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Whiplash! F.D.A. Reverses Decision and Agrees to Review Moderna's Flu Vaccine (NY Times, Wall Street Journal, Access New wire) N.I.H. Director Will Temporarily Run C.D.C. in Leadership Shake-Up (NY Times) Reduction in infant Hepatitis B Immunizations (Oregon State Health Department) Why Adenovirus vectored vaccine failed: Adenoviral Inciting Antigen and Somatic Hypermutation in VITT (NEJM) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard(South Carolina Department of Public Health) Measles Outbreak Hits Florida College (NY Times) Utah's measles outbreak reaches 300 cases (CIDRAP) Measles Is Actively Spreading in SLCo (Salt Lake County Health Department) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles 2025 (NEJM) Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens (Science; Immune 26) Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles (Science) Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands (Nature Communications) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) The risk of cardiac disease events after respiratory syncytial virus disease: a systematic literature review and meta-analysis (European Respiratory Review) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years (CDC: MMWR) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Assessing the impact of SARS-CoV-2 infection and vaccination on fertility and assisted reproductive techniques outcomes: an umbrella review (Vaccine) Long-Term Risk of Incident Type 2 Diabetes Following SARS-CoV-2 Infection: A Population-Based Study in British Columbia, Canada (Diabetes Metabolism Research and Review) Reaching out to US house representative Letters read on TWiV 1298 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

What a week we have in store! Five fabulous Top 20 matchups highlight this week's game action, including another scintillating televised battle set in the early evening on Friday and D-Fly & Dixie are here to set the table for you. This week's guest analyst is Inside Lacrosse Editor-in-Chief, Matt Kinnear. The guys discuss how the media business has radically changed and how lacrosse coverage has evolved during Matt's tenure at Inside Lacrosse. And with so many storylines in each of the big games, the guys go deep in this week's previews.This week's player guest is Johns Hopkins' top defenseman, Quintan Kilrain. While the Jays prepare for UNC, Kilrain joins the guys to talk about leaving home for high school, playing for Coach Jon Posner at Culver and Lawrenceville, being the first solo captain of the Blue Jays in 37 years, his Canadian-influenced playing style, the experience of playing for Team USA in South Korea, why he chose Hopkins and much, much more.GAME PREVIEWSFRIDAYNo. 13 Johns Hopkins (3-0) at No. 3 North Carolina (3-0) | 5 p.m. | ACCN | UNC -2.5/23.5SATURDAYNo 12 Princeton (0-1) at No. 2 Maryland (1-1) | noon | B1G+ | Maryland -2.5/21.5No. 1 Syracuse (3-0) at No. 14 Harvard (2-0) | 1 p.m. | ESPN+ | Syracuse -3/26.5No. 5 Cornell (1-0) at No. 17 Denver (3-0) | 2 p.m. | Midco Sports | Cornell -2.5/21.5SUNDAYNo. 4 Georgetown (1-0) at No. 7 Notre Dame (2-0) | 12:30 p.m. | ACCN | ND -1.5/24.5GIVE & GOIn this week's Robert Duvall-themed Give & Go, the fellas pay tribute to the legendary actor with a fun trivia game about his memorable film career.

On episode 119 of Native Land Pod, hosts Angela Rye, Andrew Gillum, and Bakari Sellers team up with guest-host Dr. Reverend Jamal Bryant. Pastor Bryant held a groundbreaking joint sermon recently with his wife, Karri Bryant, for Valentines day. They cracked jokes and shared their wisdom for how to make a relationship last, which we’ll pass on to you. Then Pastor Bryant holds space for us as we remember another reverend, Jesse Jackson, who passed away Tuesday, February 17th. FOR YOUR SITUATIONAL AWARENESS: Early voting sites are being removed from North Carolina Universities, disenfranchising Black students. The SAVE Act heads to the Senate, the “Voter ID Law” threatens voting rights. DHS Secretary Kristi Noem says DHS Will Help “Secure” Elections. The Olympic Village has run out of the 10,000 condoms it supples to athletes. Five Black surgeons lead the trauma unit at the prestigious Johns Hopkins hospital for the first time. We dedicate the majority of our show today to Reverend Jesse Jackson. Reverend Jackson had a knack for showing up wherever Black folks were organizing; he showed up for our hosts multiple times to offer his support and mentorship. We’ll hear their personal stories about the reverend and more from his fabled life: Reverend Jackson grew up in poverty before rising through the church to carry on the work of MLK Jr., his mentor. He ran for president in the 80’s (which set the stage for Obama), championed progressive causes that were far ahead of his time, and created broad political alliances that last to this day. His impact cannot be overstated. If you’d like to submit a question, check out our tutorial video: http://www.instagram.com/reel/C5j_oBXLIg0/ and send to @nativelandpod. We are 263 days away from the midterm elections. Welcome home y’all! —--------- We want to hear from you! Send us a video @nativelandpod and we may feature you on the podcast. Instagram X/Twitter Facebook NativeLandPod.com Watch full episodes of Native Land Pod here on YouTube. Native Land Pod is brought to you by Reasoned Choice Media. Thank you to the Native Land Pod team: Angela Rye as host, executive producer, and cofounder of Reasoned Choice Media; Andrew Gillum as host and producer, Bakari Sellers as host and producer, and Lauren Hansen as executive producer; LoLo Mychael is our research producer, and Nikolas Harter is our editor and producer. Special thanks to Chris Morrow and Lenard McKelvey, co-founders of Reasoned Choice Media. Theme music created by Daniel Laurent.See omnystudio.com/listener for privacy information.

Andrea has been following the Kowalski v Johns Hopkins All Children's case since it first received national attention, and previously covered it in depth in our third season. Within this 4-part series, we're revisiting the case with the benefit of additional trial testimony, released records, and appellate developments. In this first part, we're going back to 2015 to revisit the events that set this case in motion. We're sharing this recap now because the Kowalski case is directly relevant to themes we'll be exploring in season 7 of Nobody Should Believe Me. The public conversation around this case—shaped by courtroom proceedings, media coverage, and documentary storytelling—has had broader implications for how medical child abuse allegations are understood and debated.  *** Try out Andrea's Podcaster Coaching App: https://studio.com/apps/andrea/podcaster Order Andrea's book The Mother Next Door: Medicine, Deception, and Munchausen by Proxy.  Click here to view our sponsors. Remember that using our codes helps advertisers know you're listening and helps us keep making the show!   Subscribe on YouTube where we have full episodes and lots of bonus content.  Follow Andrea on Instagram: @andreadunlop Buy Andrea's books here.  For more information and resources on Munchausen by Proxy, please visit MunchausenSupport.com The American Professional Society on the Abuse of Children's MBP Practice Guidelines can be downloaded here. Learn more about your ad choices. Visit podcastchoices.com/adchoices

ICE, Noem and The War on Free Elections. Ukraine Won the Olympics. Prince Andrew Arrested in England Over Epstein Ties. Hegseth, Tuberville Continue to Embrace Dumb Ideas. Spring Training a Homerun. The drumbeats of war are growing louder. In this solo episode of Independent Americans, host Paul Rieckhoff reports that President Trump has signaled the U.S. military could strike Iran within ten days — with zero congressional authorization, zero public debate, and zero accountability. Congress is rolling over, America's sons and daughters are in harm's way, and the American people deserve a vote. Meanwhile at home, Paul holds nothing back on DHS Secretary Kristi Noem, who reportedly pulled a Coast Guard search-and-rescue aircraft away from a missing 21-year-old service member to prioritize a deportation flight, and on ICE's escalating cruelty — including a nine-year-old girl detained in San Antonio for eight months and the heartbreaking death of Ophelia Torres, a 16-year-old who fought cancer while her father was held by ICE. These are not statistics. Paul refuses to let their stories disappear. Pentagon Secretary Pete Hegseth's culture war rages on. Paul breaks down Hegseth's move to block military members from enrolling at Harvard, Duke, Johns Hopkins, and dozens more elite universities — followed by the VA's decision to strip veterans of their post-9/11 GI Bill benefits at those same schools. Denmark, one of America's most steadfast NATO allies, now views the U.S. as an adversary, with 60% of Danes saying so. Paul also covers Venezuela strikes without congressional approval, the staggering losses in Ukraine, and a personal word about the courage of Stephen Colbert and the growing chorus of ordinary Americans pushing back. Paul closes on something good: spring training. He was at Yankees practice in Tampa Bay this morning, where his boys got balls signed by Aaron Judge — proof that community, access, and joy are still very much alive. Episode 445 ends with a clear mission: country over party, people over politics. If you're among the 45% of Americans who call themselves independent, this is your show. Stay vigilant. -WATCH video of this episode on our YouTube channel. -Learn more about Paul's work to elect a new generation of independent leaders with Independent Veterans of America. -Learn more about American Veterans for Ukraine here. Connect with Independent Americans: Subscribe on YouTube, Spotify, Apple Podcasts, and all podcast platforms Read more at Substack Support ad-free episodes at Patreon  Connect: Instagram  • X/Twitter • BlueSky • Facebook  Follow on social: @PaulRieckhoff on X, Instagram, Threads, and Bluesky -Join the movement. Hook into our exclusive Patreon community of Independent Americans. Get extra content, connect with guests, meet other Independent Americans, attend events, get merch discounts, and support this show that speaks truth to power.  -And get cool IA and Righteous hats, t-shirts and other merch now in time for the new year.  Independent Americans is powered by veteran-owned and led Righteous Media.  And now part of the BLEAV network!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde sits down with Daniel Yoo, CEO and founder of FinMate AI, to explore what happens when deep wealth-management experience meets real, pre-hype AI expertise. Daniel shares lessons from serving as a Senior Financial Advisor overseeing $800M in client assets, how his Johns Hopkins research on AI forecasting shaped his view of markets, and why he built FinMate AI to help advisors boost productivity, strengthen client relationships, and improve retention. What can AI actually do for financial advisors today, and what's still hype? How do behavioral biases show up during volatility, and how should investors guard against them? What does "secure, compliant AI" really mean in financial services? And as economic forces keep shifting, what will the AI-enabled advisor look like in the next five years? Tune in for a practical, honest conversation on AI, investing trends, client trust, and the future of wealth management.Quick question: when you buy something handmade, do you ever wonder who made it, and where your money really goes? Lembrih is building a marketplace where you can shop Black and African-owned brands and learn the story behind the craft. And the impact is built in: buyers can support vendors directly, and Lembrih also gives back through African-led charities, including $1 per purchase. They're crowdfunding on Kickstarter now. Back Lembrih at lembrih.com, or search “Lembrih” on Kickstarter.Support the show

Dr. Earl Campazzi discusses his book "Better Health with AI" and using AI to improve long-term health and boost early detection. Earl is a Johns Hopkins–trained physician specializing in preventive and personalized medicine. Listen as we explore the health benefits of using wearable devices, collected data, and AI while preserving the essential human relationship between patients and doctors. Host, Kevin Craine Do you want to be a guest? https://DigitalTransformationPodast.net/guest Do you want to be a sponsor? https://DigitalTransformationPodcast.net/advertise

IMS Radio – Be The Best Podcast – Season 1, Episode 2 Maryland men's lacrosse alumni Emmett Cahill and PLL All-Pro defenseman Matt Dunn make guest appearances on this week's “Be the Best Podcast.” Emmett and Matt catch us up on their lives since graduating from College Park. The whole group reviews the Maryland's 11-9 loss at Syracuse. The group then zooms out on some games of interest around the country last week, including the Richmond-UVA game and the Loyola-Johns Hopkins game. Before previewing Maryland's upcoming game against Princeton, the group goes over Princeton's loss to Penn State last week. Finally, the group zooms around to preview other national games of interest. We talk about Denver's unique schemes ahead of their game against Cornell. We preview the North Carolina and Johns Hopkins game in Chapel Hill on Friday. Finally, we preview Georgetown's visit to Notre Dame on Sunday for a matchup of Top 10 teams. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Five states have begun banning soda and candy purchases through SNAP — with 18 states seeking similar waivers. Is this smart public health policy or government overreach? Michael speaks with Dr. Julia Wolfson of Johns Hopkins to break down how SNAP works, why 42 million Americans rely on it, and whether restricting “junk food” will improve health — or deepen stigma. From slippery slope concerns to the politics behind the policy, this is a thoughtful look at one of the most debated changes to food assistance in decades. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this Bright Spots in Healthcare episode, Medicare Advantage leaders confront a hard truth: high activity does not guarantee high impact. As Stars cut points rise and margins tighten, traditional segmentation and broad outreach strategies are no longer sufficient. This discussion explores how leading plans are shifting from static stratification to dynamic signal monitoring, identifying which members are realistically movable, and embedding behavioral intelligence directly into operational workflows. The focus is not on doing more. It is on doing what measurably drives lift. Our guests include: Amin Serehali, Chief Data and Analytics Officer, Independent Health Mike Leiper, Director of Government Quality Programs, Highmark Brendan Generelli, Director of Medicare Stars and Quality, Johns Hopkins Health Plans David Burianek, Chief Strategy Officer for Health Plans, MedOrion Together, they explore: How plans are distinguishing between theoretical risk and practical movability, concentrating outreach on members whose behavior can realistically change within a defined window. How leading organizations are integrating claims, pharmacy, grievance, complaint, and social drivers data with behavioral science modeling to move beyond rules based campaigns. Why simultaneous pressure across HEDIS, CAHPS, and Part D often reflects fragmentation in engagement strategy rather than isolated measure failures. How targeted pilots within defined populations create clarity before scaling enterprise wide changes. Why timing is emerging as a strategic lever, with continuous signal monitoring replacing annual segmentation refresh cycles. How embedding intelligence into frontline workflows improves alignment between engagement effort and measurable Stars influence. Panelist Bios: https://www.brightspotsinhealthcare.com/events/beyond-segmentation-how-medicare-advantage-engagement-is-being-rebuilt/ Download the Episode Guide: Get key takeaways and expert highlights to help you apply lessons from the episode. https://www.brightspotsinhealthcare.com/wp-content/uploads/2026/02/Updated-Episode-Guide-Beyond-Segmentation.docx.pdf  Key Insights Summary: Find the top six strategic insights from the discussion, including detailed speaker takeaways and moderator notes. https://www.brightspotsinhealthcare.com/wp-content/uploads/2026/02/Key-Takeaways-Beyond-Segmentation-2.12.26.docx.pdf    Resources: Companion Brief: From Segmentation to Signals This companion brief expands on the behavioral intelligence framework discussed in the episode, outlining how health plans can identify movable phenotypes, align engagement timing with readiness signals, and measure causal lift against specific Stars drivers. Inside you will find insights on: Shifting from annual risk stratification to continuous behavioral signal monitoring Identifying members whose behavior is realistically influenceable within a defined measurement window Reducing wasted outreach and improving ROI through precision targeting Embedding intelligence into operational workflows rather than post hoc reporting To request your copy, email nroberts@brightspotsventures.com. Thank You to Our Episode Partner, MedOrion: Medorion partners with Medicare Advantage plans to integrate behavioral science and advanced analytics into engagement strategy. By layering behavioral phenotyping onto clinical and utilization data, Medorion helps plans identify which members are movable, optimize outreach timing, and improve measurable Stars performance. Learn more at https://medorion.com/. Schedule a Conversation with MedOrion: To explore how behavioral intelligence can strengthen your engagement strategy and improve measurable lift across HEDIS, CAHPS, and Part D, reach out to nroberts@brightspotsventures.com  to schedule a discussion with David Burianek and the Medorion team. About Bright Spots Ventures: Bright Spots Ventures helps healthcare leaders separate signal from noise and accelerate the adoption of what works. We bring health plan, provider, and innovation leaders together through curated content and high-trust convenings to build meaningful relationships and turn insight into action. Explore our podcast at www.brightspotsinhealthcare.com.

Neuroscience expert Dr. Mark Hobson reveals why educators MUST understand how AI works—and why your brain learns exactly like AI does.What You'll Learn:The shocking AI gap between business and educationHow your brain processes information (90% through emotions—AI can't)Why banning AI fails studentsPractical ChatGPT strategies for classroomsThe 4 Rs: Read, Recite, Repeat, RememberHow AI mimics your neural networksWhy "intentional screen time" beats screen time limitsKey Quote: "Our learners need to know more about AI and how it works—and so do our faculty." - Dr. Mark HobsonDr. Hobson studied at Johns Hopkins & Northeastern, specializing in mind, brain, and teaching. He breaks down neuroscience into actionable ed strategies.Chapters00:00 Introduction and Guest Background04:59 The Impact of AI on Education09:53 Neuroscience and AI: A Learning Link14:55 The Role of Emotion in Learning19:43 AI's Influence on Student Learning24:44 Shared Learning Principles: AI and the Brain29:41 The Future of AI in Education34:19 Final Thoughts and ReflectionsSponsor ShoutoutThank you to our sponsors: Book Creator, Eduaide.AI, and Peel Back Education for supporting My EdTech Life.Get 3 Months of Book Creator Premium Access Free!Use Code: MyEdTechLifeStay Techie ✌️Peel Back Education exists to uncover, share, and amplify powerful, authentic stories from inside classrooms and beyond, helping educators, learners, and the wider community connect meaningfully with the people and ideas shaping education today. Authentic engagement, inclusion, and learning across the curriculum for ALL your students. Teachers love Book Creator.Support the show

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are shocked by recent events, including Dr. Oz's appeal for measles vaccination, Vinjay Prasad's unilateral rejection of Moderna's mRNA influenza vaccine application, and the increasing number of New World screw worm cases, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, the number of measles deaths in Mexico, long COVID treatment center, where to go for answers to your long COVID questions, choroid plexus alterations in long COVID association with neuropathologies and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode How Dr. Oz's appeal to get measles vaccine may differ from RFK Jr.'s messaging (ABC News) FDA reverses course, refuses to review Moderna's application for new mRNA flu vaccine (CIDRAP) Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit (American Academy of Pediatrics: Pediatrics) US Olympic Committee remains 'dialed in' to prevent spread of stomach illness at Winter Games (CNN) Oz promotes measles vaccination (NY Times; USA Today; Fortune) Screw worm in Mexico (Gobierno de Mexico) Mexico reports more human New World screwworm infections (CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles outbreak poses risk of 'irreversible' brain damage, health officials warn (Fox News) In Mexico, at least 28 have died from measles outbreak that started 2025 (Reuters) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza vaccination and the risk of myocardial infarction(BMC Publich Health) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database (Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks (Alzheimer's & Dementia) Reaching out to US house representative Letters read on TWiV 1296 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

#689: Most people think forgetting a name means their brain is failing.  Dr. Majid Fotuhi, a neurologist who taught at Johns Hopkins and Harvard, sees thousands of patients convinced they have Alzheimer's – only to discover they're dealing with poor sleep or stress. Dr. Fotuhi joins us to break down the difference between cognitive decline, dementia and Alzheimer's disease. He explains why chronic stress physically shrinks your hippocampus — the thumb-sized memory center in your brain — and how twelve weeks of lifestyle changes reversed cognitive decline in 84 percent of his patients. We talk about the five hidden taxes draining your brain: sedentary lifestyle, poor sleep, junk food, chronic stress and mental laziness. Scrolling social media after work counts as mental laziness, even if your day job involves intense focus. Dr. Fotuhi offers a different framework: five pillars that compound over time. Exercise ranks first because it multiplies mitochondria in your brain cells, reduces inflammation and generates new neurons in your hippocampus. Walking 10,000 steps daily cuts Alzheimer's risk by 50 percent. Sleep comes second. Your brain rinses itself during deep sleep, flushing out amyloid — the core protein in Alzheimer's disease. One night of poor sleep increases amyloid in your brain. We cover nutrition (skip the junk food debate), mindset (heart rate variability breathing reduces Alzheimer's footprints) and brain training. Dr. Fotuhi memorizes 70 names in a single lecture and explains his technique for remembering credit card numbers using mental imagery. The conversation covers London taxi drivers who grew their hippocampus by memorizing 10,000 streets, why stress management beats supplements, and how Swedish students learning Arabic increased their brain volume in three months. Timestamps: Note: Timestamps will vary on individual listening devices based on dynamic advertising segments. The provided timestamps are approximate and may be several minutes off due to changing ad lengths. (00:00) Defining cognitive decline, dementia and Alzheimer's disease (05:19) Why cognitive issues don't always mean Alzheimer's (07:24) Thinking of your brain as an asset to manage (07:51) The five hidden taxes draining your brain (10:45) How poor sleep prevents brain rinsing and causes inflammation (14:20) Oral health and brain health connection (16:40) Brain plasticity and the Broca lobe (27:02) The five pillars of brain health (35:23) Cardiovascular fitness versus strength training for brain health (38:51) Sleep as the second pillar of brain health (48:05) When exercise beats sleep (51:33) Different types of intelligence beyond IQ tests (1:03:53) Reversing brain damage from decades of bad habits (1:10:25) Nutrition and avoiding junk food (1:25:09) Mindset and stress management as pillar four (1:33:35) Breathing exercises for stress reduction (1:39:24) Brain training as the fifth pillar (1:51:52) Memory techniques for names and numbers (2:02:46) Nootropics and supplements for brain health Learn more about your ad choices. Visit podcastchoices.com/adchoices

The 2026 season is barely out of the womb, and we're already blessed with a No. 1 vs. No. 2 matchup in a standalone TV window. You can bet D-Fly & Dixie are excited. With a couple of other Top 20 matchups on tap, this is a loaded show. They are joined by long-time friend of the pod and guest analyst Christian Sweezy, who shares insights on why this is Georgetown's year and discusses his new book, “The Long Red Line.”This week's interview is with Maryland's All-American lockdown defender, Will Schaller. We discuss his hockey background, why he chose Maryland, the benefits of knowledgeable parents, his relationship with Coach Bernhardt, the high expectations for Terps defensemen, pit beef and much, much more. You won't want to miss it.GAME PREVIEWSFRIDAYNo. 1 Maryland (1-0) at No. 2 Syracuse (2-0) | 6 p.m. | ACCN | Maryland -1.5/23.5SATURDAYNo. 14 Penn State (1-1) at No. 3 Princeton (0-0) | noon | ESPN+ | Princeton -4.5/25.5No. 13 Virgina (1-0) at No. 8 Richmond (1-0) | noon | ESPN+ | Richmond -1.5/24.5Loyola (0-1) at No. 14 Johns Hopkins (2-0) | 1 p.m. | ESPN+ live, ESPNU on Feb. 15 | JHU -3.5/22.5No. 4 Cornell (0-0) at UAlbany (0-0) | 1 p.m. | ESPN+ | Cornell -4.5/24.5 GIVE & GOIn this week's Valentine's Day-themed Give & Go, the fellas produce a Top 5 list of their favorite “Love” songs.

In this 20-minute episode of RISE Radio, Editorial Director Ilene MacDonald sits down with Dr. Matt Lambert, the former chief medical officer at Reveleer, to unpack the rapidly evolving landscape of Medicare Advantage risk adjustment. Together, they discuss the implications of the 2027 Advance Notice, new OIG compliance guidance, and the industry's shift toward encounter-based, prospective risk adjustment. Dr. Lambert explains how hybrid AI—combining generative AI with long‑standing clinical rules—can improve accuracy, reduce false positives, and streamline workflows for providers, payers, and risk adjustment teams. He also shares practical strategies for organizations beginning this transition, emphasizing partnership, user‑friendly workflows, and technology that meets clinicians at the point of care.About Matt Lambert, M.D. Dr. Matt Lambert, is the former chief medical officer at Reveleer and a leader in health care innovation, blending clinical expertise with technology, policy, and payment strategies. He previously served as CMO of Curation Health (acquired by Reveleer in 2024) and led digital transformation at Clinovations and The Advisory Board. He has been CMIO for New York City Health + Hospitals, RWJ Barnabas, and Johns Hopkins, overseeing Epic and Cerner implementations. An emergency medicine physician for 20+ years, he authored two books on health care reform. He earned his MD from Marshall University and trained at West Virginia University. About ReveleerReveleer, a health care software and services company, uses machine learning and intelligent automation technology to empower health plans control over their quality improvement, risk adjustment, and member management programs. With one transformative solution, Reveleer allows plans to independently execute and manage provider outreach and data retrieval, coding, abstraction, member management, and reporting. Reveleer leverages proprietary technology, robust data sets, and subject matter expertise, so health plans can execute programs that deliver value and improved outcomes. Click here for Reveleer's Guide to AI in Value-Based Care.

IMS debuts its “Be The Best” podcast, which covers the University of Maryland's men's lacrosse program. In this episode, the Terps' 19-10 opening game win over in-state rival Loyola is discussed. Despite slow start on offense, Maryland's transfers from Yale paced the offense, as did a transfer at the face-off X. Younger players getting their first significant experiences also made contributions, as did the return of a goalie who started for the 2024 season. The hosts also do a quick spin around games of national interest - Virginia's win over Colgate, North Carolina's escape against Jacksonville, Villanova's overtime win at Penn State, and others – before getting into a preview of Friday's road tilt against Syracuse. Finally, we note some national games of interest – Virginia at Richmond, Penn State at Princeton, and Loyola at Johns Hopkins. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Dr Bill Nelson talks with Dr Richard Dotson about his book, Unbroken, detailing the story of his diagnosis, treatment, and recovery from pancreatic cancer. Dr Dotson's oncologist at Johns Hopkins, Dr Daniel Laheru, also joins the podcast to discuss his diagnosis and care plan. Learn more about Dr Dotson's book ➡️ https://amzn.to/4qJfVCp

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population, the importance of PSA doubling time as a prognostic factor and with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. David Einstein and Dr. Ravi Madan. Dr. Einstein is a medical oncologist specializing in genitourinary malignancy working at Beth Israel Deaconess Medical Center, part of the DFCI Cancer Center, and an assistant professor at Harvard Medical School. Dr. Madan is a senior clinician at the National Cancer Institute (NCI), where he focuses on conducting clinical research in prostate cancer, particularly in the field of immunotherapy. Today, we will be discussing the article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." So, thank you for speaking with us, Dr. Einstein and Dr. Madan. David Einstein: Thanks for having us. This is a great pleasure. Ravi Madan: Appreciate being here. Davide Soldato: So, I just want to start from a very wide angle. And the main question is why did you feel that there was the need to convey a consensus and a working group to talk about this specific topic: biochemically recurrent prostate cancer? What has been the change in current clinical practice and in the trial design that we are seeing nowadays? And so, why was it necessary to convey such a consensus and provide considerations on novel clinical trials? David Einstein: Yeah, so I think it's very interesting, this disease state of biochemically recurrent prostate cancer. It's very different from other disease states in prostate cancer, and we felt that there was a real need to define those differences in clinical trials. Years ago, metastatic castration-resistant prostate cancer was the primary disease state that was explored, and over time, a lot of things shifted earlier to metastatic disease defined on a CAT scan and bone scan to an earlier disease state of metastatic castration-sensitive prostate cancer. And the clinical trial principles from late-stage could be applied to MCSPC as well. However, BCR is very different because the patients are very different. And for those reasons, there are unique considerations, especially in terms of toxicity and treatment intensity, that should be applied to biochemically recurrent prostate cancer as opposed to just using the principles that are used in other disease states. And for that reason, we thought it was very important to delineate some of these considerations in this paper with a group of experts. Davide Soldato: Thanks so much. So, one of the main changes that have been applied in recent years in clinical practice when looking at biochemically recurrent prostate cancer is the use of molecular imaging and particularly of PSMA PET. So, first of all, just a quick question: was the topic of the consensus related on which threshold of PSA to use to order a PET scan to evaluate this kind of patient? David Einstein: Yeah, thanks for that question. It's a super important one. The brief answer is that no, we did not address questions about exactly when clinicians would decide to order scans. We were more concerned with the results of those scans in how you define different disease states. But I think as a broader question, I think a lot of folks feel that finding things on a scan equates that with what we used to find on conventional scans. And fundamentally, we actually sought to redefine that disease space as something that's not equivalent to metastatic disease, and rather coined the term "PSMA-positive BCR" to indicate that traditional BCR prognostic criteria and factors still apply, and that these patients have a distinct natural history from those with more advanced metastatic disease. Ravi Madan: And if I may just add that the National Cancer Institute is running a trial where we're prospectively monitoring PSMA-positive BCR patients. And that data is clearly showing that, much like what we knew about BCR a decade ago, PSMA findings in BCR patients do not change the fact that overall, BCR is an indolent disease state. And the findings, which are usually comprised of five- to seven-millimeter lymph nodes, do not endanger patients or require immediate therapy. And so, while PSMA is a tool that we can be using in this disease state, it doesn't really change the principal approach to how we should manage these patients. And as Dr. Einstein alluded to, there is a drive to create a false equivalency between PSMA-positive BCR and metastatic castration-sensitive prostate cancer, but that is not supported by the data we're accumulating or any of the clinical data as it exists. Davide Soldato: One thing that it's very important and you mentioned in your answer to my question was actually the role of PET scan and conventional imaging, so CAT scan and bone scan that we have used for years to stage patients with metastatic prostate cancer. And you mentioned that there is a distinction among patients who have a positive PET scan and a BCR, and patients who have a positive conventional imaging. And yet, we know that sometimes the findings of the PET scan are not always so clear to interpret. So, I just wanted to understand if the consensus reached an agreement as to when to use conventional imaging to potentially resolve some findings that we have on PET scan among thess patients with BCR? David Einstein: Yeah, I think there's a number of questions actually buried within that question. One of which is: does PSMA PET result in false positives? And the answer has definitely been yes. There's a known issue with false-positive rib lesions. And so, first and foremost, we need to be very careful in calling what truly is suspicious disease and what might actually not be cancer or might be something that is totally separate. So I think that's the first part of the answer to that question. The second is to what extent do we need to use paired PET and conventional imaging to define this disease state? In other words, do you have to have positive findings on one and negative findings on the other in order to enter this definition? The challenge there, as we discussed, is that logistically, oftentimes it's hard to get patients to do multiple sets of scans to actually create that definition. Sometimes it's difficult to get insurers to pay for such scans. And finally, it's hard to sometimes blind radiologists to the results of one scan in reading the other. So, we did have some deliberations about to what extent you could use some of the CAT scan portion of a PSMA PET in order to at least partially define that. We also talked about using bone scans to confirm any bone findings seen on PET. But I think another important part of this is not just the baseline imaging, but also what's going to be done serially on a study in order to define responses and progression. And that's sort of a whole separate conversation about to what extent you can interpret changes in serial PET. Ravi Madan: And just to pick up on the key factor here, I think that the PSMA PET in BCR is pretty good at defining lymph node disease, and that's actually predominantly 80 to 90 percent of the disease seen on these findings. It might be pretty good at also defining other soft tissue findings. The real issues come to bone findings. And one thing the group did not feel was appropriate was to just define only PSMA-positive bone findings confirmed on a CT bone window. There's not really great data on that, but the working group felt that, when in the rare situation, because it is relatively rare, a PSMA-positive finding is in a bone, a bone scan should be done. And it's worth noting that Phu Tran, who is a co-author and a co-leader of this working group, his group has already defined that underlying genomics of conventionally based lesions, such as bone scan, are more aggressive than findings on next-gen imaging, such as PSMA. So, there is also a genomic underlying rationale for defining the difference between what is seen on a PET scan in a bone and what is seen on a bone scan. Davide Soldato: Coming back to this issue of PET PSMA sometimes identifying very small lesions where we don't see any kind of correlates on conventional imaging or where we see only very little alteration on the bone scan or in the CT scan, was there any role that was imagined, for example, for MRI to distinguish this type of findings on the PET scan? Ravi Madan: So, I think that, again, what can be identified on a PSMA frequently cannot be seen on conventional imaging. We didn't feel that it was a requirement to get an MRI or a CT to necessarily confirm the PSMA findings. I think that generally, we have to realize that in this disease state, that questionable lesions are going to be seen on any imaging, including PSMA. We've actually probably put way too much faith in PSMA findings thus far, as Dr. Einstein alluded to with some of the false positives we're seeing. So, I think that these false positives are going to have to be baked into trials. And in terms of clinical practice, it highlights the need to again, not overreact to everything we see and not necessarily need to biopsy everything and put patients' health in jeopardy to delineate a disease that's indolent anyway. Davide Soldato: Thanks so much. That was very clear. So, basically, the main driver was really also the data showing that if we have a BCR, so a patient with a biochemically recurrent disease that is positive on the conventional imaging, this is usually associated with a different aggressiveness of the disease. But coming back to a comment that you made before, Dr. Madan, you said that even if we talk about PSMA-positive BCR, we are still talking about BCR and the same criteria should apply. So, what we have used for years in this space to actually try to stratify the prognosis of patients is the PSA doubling time, so how quickly the PSA rises over time. So, coming back to that comment, was the consensus on the PSA doubling time basically retained as what we were using before, so defining patients with a doubling time less than 12 months, 10 months, 9 months, as patients with a higher risk of progressing in terms of developing metastatic disease? Ravi Madan: Yes, so that's a very important point. And the working group defined high-risk BCR as a PSA doubling time less than six months. And this really comes from Johns Hopkins historical data, which shows that if your doubling time is three months or less, there's about a 67 percent chance of metastasis at five years. If it's between three and six months, it's 50 percent. And if it's over six months, if it's between six and nine months, it's roughly only 27 percent. There are trials that are accruing with eligibility criteria that they may describe as high-risk that are beyond six months, but the data as really it's been defined in the literature highlights that truly high-risk BCR is less than six months. And the working group had a consensus on that opinion, and that was our recommendation. David Einstein: And I think an important follow-on to that is that's regardless of PET findings, right? And so, we present a couple of case studies of patients with positive PET findings who have a long doubling time, in whom the disease is in fact indolent, as you would have expected from a traditional BCR prognostic standpoint. Obviously, there are patients in whom they have fast doubling times, and even if they do not have PET findings, that doesn't make them not high-risk. Ravi Madan: And just to follow up that point, I will let you know a little bit of a free preview that my colleague Melissa Abel from the NCI will be presenting PSMA findings in the context of PSA doubling time at ASCO GU if that data is accepted. Davide Soldato: Looking forward for those data because I think that they're going to clarify a lot of the findings that we have in this specific population. And coming back to one of the points that we made before, so PET PSMA has a very high ability to discriminate also a very low burden of disease, which we currently refer to as oligometastatic biochemically recurrent prostate cancer, which is not entirely defined as an entity. But what we are seeing both in some clinical trials, which use mainly conventional imaging, but also what we're starting to see in clinical practice, is that frequently we use the metastasis-directed therapy to treat these patients. So, just a little bit of a comment on the use of this type of strategy in clinical practice and if the panel thought of including this as, for example, a stratification criteria or mandated in the design of novel clinical trials in the field of BCR? David Einstein: Yeah, I think that's an incredibly important point. You know, fundamentally, there's a lot of heterogeneity in practice where some folks are using local salvage approaches, some are using systemic therapies, in some cases surveillance may be reasonable, or some combination of these different strategies. We certainly have phase two data from multiple trials suggesting that met-directed therapy may help buy patients time off of treatment until subsequent treatments are started. And that in and of itself may be an important goal that we can come back to in discussing novel endpoints. I think what our panel acknowledged was that, in some sense, the clinical practice has gotten even farther ahead than where the data are, and this is being offered pretty routinely to patients in practice. And so, what became clear was that we, in developing clinical trials, cannot forbid investigators from doing something that would be within their usual standard of care, even if it might not be supported by the most robust data. But at minimum, it definitely should be used as a stratification factor, or in some trial designs, you can do met-directed therapy after a primary endpoint is assessed. And that offers a compromise between testing, say, the effect of a systemic therapy but also not excluding patients and investigators from doing what they would have done had they not been on a study. Ravi Madan: And I would just like to follow up your phrasing in the question of "oligometastatic prostate cancer." We have a figure in the paper and it highlights the fact that, unfortunately, that term in prostate cancer is imaging agnostic. And we've already discussed in this podcast, as well as in the paper, that imaging used to define a metastatic lesion, whether it's PSMA or conventional imaging, carries with it a different clinical weight and a different prognosis. So, we feel in the working group, that the correct term for this disease state of PSMA-positive BCR is just that: PSMA-positive BCR. We also have to realize that when we talk about oligometastatic disease, while it's imaging agnostic, it seems to be numerically based, whether it's five or three or 10 depending on the trial. But PSMA-positive BCR does not have a limit in terms of the number of lesions. And so again, we just feel that there is an important need to delineate what we're seeing in this disease state, which again is PSMA-positive BCR, and that should be differentiated frankly from oligometastatic disease defined on other imaging platforms. David Einstein: Right, and that also makes clear that patients can have polyfocal disease on PET that still is not what we would consider metastatic, but goes beyond the traditional definition of oligometastatic. So, in other words, just because someone has PET-detected disease only, that does not automatically equate with oligometastatic. Davide Soldato: Thanks so much. So, you were speaking a little bit, Dr. Einstein, about the different types of treatment that we can propose or not propose to this patient because you mentioned, for example, that in clinical practice MDT, so metastasis-directed therapy, is becoming more and more used. For these patients, we can potentially use systemic treatments, which include androgen deprivation therapy, which can be given continuously or in an intermittent fashion. And recently, we can also use novel systemic therapies, for example, enzalutamide, to treat this type of patient. So, given that the point of the consensus was really to provide consideration for novel clinical trials in this space, what was the opinion on the panel regarding the control arm? So, if we're looking at a novel therapy in the BCR space, does the control arm need to include a therapy or not? And if so, which therapy? David Einstein: Yeah, this is a super important question and one that's subject to a lot of discussion, especially in light of recent data from EMBARK. What we came to a consensus around was the fact that neither MDT nor systemic therapy should be required as a control arm on BCR trials. And we can talk about a number of reasons for that. There's also the pragmatics of what investigators might actually accrue patients to and what they would consider their standard of care, and that's important to factor in, too. I think that one of the major goals of our working group was outlining what kinds of trials we would like to see in the future and where the limitations of the current data stand. For example, EMBARK proposes a strategy of a single treatment discontinuation and resumption at a predefined threshold indefinitely. That's probably not how most people are practicing. Most folks are probably using some version of intermittent therapy as they would have before this trial, but we actually don't have any data supporting that. Moreover, we don't have data comparing different intermittent strategies to one another. We don't know what the right thresholds are, we don't know how much time we buy patients off treatment, and we don't know to what extent MDT modifies that. And so, those are all really important questions to be asking in future versions of these trials. I'd say my second point would be that a lot of drug development is happening with novel therapies that are not hormonal, trying to bring them into this space. And when you think about trying to compare one of those types of therapies to a hormonal therapy on short-term endpoints, the hormonal therapy is always going to win. Hormonal therapy is almost universally effective, it will bring down PSAs, and it will prolong, quote-unquote, "progression." The downside of that is that hormonal therapy doesn't actually modify the disease, it suppresses it, and it tends to have fairly transient effects once you remove it. And so, part of our goal was in trying to figure out some novel endpoints that would allow these novel types of therapies to be examined head-to-head against a more traditional type of hormonal therapy and have some measurement of some of the more long-term impacts. Davide Soldato: So, jumping right into the endpoints, because this is a very relevant and I think very well-constructed part of the paper that you published. Because in the past we have used some of these endpoints, for example, metastasis-free survival, as potentially a proxy for long-term outcomes. But is this the right endpoint to be using right now, especially considering that frequently this outcome is measured using conventional imaging, but we are including in these trials patients who are actually negative on conventional imaging but have a positive PSMA when they enter this type of trial? David Einstein: Yeah, there's a number of challenges with those types of endpoints. One of which is, as you say, we're changing the goalposts a little bit on how we're calling progression. We still don't exactly understand what progression on PET means, and so that's something that is challenging. That said, we're also cognizant of the fact that many times investigators are likely to get PET scans in the setting of rising PSA, and that's going to affect any endpoint that relies purely on conventional imaging. So, there's some tension there between these two different sets of goalposts. One thing that we emphasize is that not only are there some challenges in defining those, but also there're challenges in what matters to a patient. So, if a progression event occurs in the form of a single lesion on a PET scan or even a conventional image, that might be relevant for a clinical trial but might be less relevant for a patient. In other words, that's something that, in the real world, an investigator might use serial rounds of metastasis-directed therapy or intermittent therapy to treat in a way that doesn't have any clinical consequences for the patient necessarily. In other words, they're asymptomatic, it's not the equivalent of a metastatic castration-resistant disease progressing. And so, we also need to be cognizant of the fact that if we choose a single endpoint like PFS, that there's going to be many different versions of progression, some of which probably matter clinically more than others, and some of which are more salvageable by local therapies than others. Ravi Madan: So I think the working group really thoughtfully looked at the different options and underscored perhaps strengths and weaknesses, and I think that's presented as you mentioned in the paper. But I think it's also going to depend on the modality, the approach of the therapeutic intervention. In some cases if it's hormone-based, then maybe PSA is providing some early metrics, maybe metastasis-free survival is more relevant in a continuous therapy, but intermittent therapies might have a different approach. There's emerging immunotherapy strategies, radiopharmaceutical strategies, they might have some more novel strategies as well. I think we have to be open-minded here, but we also have to be very clear: we do not know what progression is on a PSMA scan. Just new lesions may not carry the clinical significance that we think, and we may not know what threshold that ultimately becomes clinically relevant is. So, I do think that there was some caution issued by the working group about using PSMA as an endpoint because we still do not have the data to understand what that modality is telling us. Again, I'm optimistic that the National Cancer Institute's prospective data set that we've been collecting, which has over 130 patients now, will provide some insights in the months and years ahead. Davide Soldato: So, just to ask the question very abruptly, what would you feel like the best endpoint for this type of trials is? I understand that is a little bit related to the type of treatments that we're going to use, whether it's intermittent, whether it's continuous, but do we have something that can encapsulate all of the discussion that we have up until this point? David Einstein: Yeah, so that's a perfect segue to the idea of novel endpoints, which we feel are very important to develop in these novel disease spaces. So, one thing that we discussed was an endpoint called treatment-free survival, which conceptually you can think of as exactly what it sounds like, but statistically you actually have to do some work to get there. And so essentially, you imagine a series of Kaplan-Meier curves overlaid: one about overall survival, one time to next therapy, one time on initial therapy. You can actually then take the area under those curves or between those curves and essentially sum it up using restricted mean survival time analysis. And that can give you a guide about the longitudinal experience of a patient: time spent on treatment versus off treatment; time spent with toxicity versus without toxicity. And importantly, each one of those time-to-event metrics can be adjusted depending on exactly what the protocol is and what is allowed or not allowed and what's prespecified as far as initiation of subsequent therapies. So, we felt that this was a really important endpoint to develop in this disease space because it can really capture that longitudinal aspect. It can really reward treatments that are effective in getting durable responses and getting patients off of therapy, because unfortunately, PFS-based endpoints generally reward more or longer systemic therapy versus shorter or no systemic therapy, and that's sort of an artificial bias in the way those endpoints are constructed. So, I think that there are challenges of course in implementing any new endpoint, and some of the things that are really critical are collecting data about toxicity and about subsequent therapies beyond what a typical trial might collect. But I think in this kind of disease space, that longitudinal aspect is critical because these are really patients who are going to be going through multiple rounds of therapy, going to be going on and off treatments, they're going to be using combinations of local and systemic therapies. And so, any one single endpoint is going to be limited, but I think that really highlights the limitations of using PFS-based endpoints in this space. Ravi Madan: I also think that in the concept of treatment-free survival lies one of the more powerful and, honestly, I was surprised by this, that it was so universally accepted, recommendations from the committee. And that was that the general approach to trials in this space should be a de-escalation of the EMBARK strategy as it's laid out with relatively continuous therapy with one pause. And so, I think again, buried in all of this highlights the need for novel endpoints like treatment-free survival. We get to the fact that these are patients who are not at near-term clinical risk from symptoms of their disease, so de-escalating therapies does not put them at risk. And if you look at, for example, lower-volume metastatic castration-sensitive prostate cancer, it's become realized that we need to de-escalate, and there are now trials being done to look at that. Historically, we know that BCR is an indolent disease process for the vast majority of patients who are not at near-term risk from clinical deterioration. So, therefore, we shouldn't wait a decade into abundant BCR trials to de-escalate. The de-escalation strategy should be from the outset. And that was something the committee really actually universally agreed on. David Einstein: And that de-escalation can really take multiple forms. That could be different strategies for intermittent therapy, different start-stop strategies. It could also mean actually intensifying in the short-term with the goal long-term de-intensification, kind of analogous to kidney cancer where we might use dual checkpoint inhibitors up front with some higher upfront toxicity but with the hope of actually long-term benefit and actually being able to come off treatment and stay in remission. Those kinds of trade-offs are the types of things that are challenging to talk about. There's not a one-size-fits-all answer for every patient. And so, that's why some of these endpoints like treatment-free survival would be really helpful in actually quantifying those trade-offs and allowing each patient to make decisions that are concordant with their own wishes. Davide Soldato: Thanks so much. That was very clear, especially on the part of de-escalation, because, as you were mentioning, I think that we are globally talking about a situation, a clinical situation, where the prognosis can be very good and patients can stay off treatment for a very long period of time without compromising long-term outcomes. And I think that well-constructed de-escalation trials, as you were mentioning and as the consensus endorsed, are really needed in this space also to limit toxicity. This brings us to the end of this episode. So, I would like to thank again Dr. Einstein and Dr. Madan for joining us today. David Einstein: We really appreciate the time and the thought, and I think that even starting these types of discussions is critical. Even just recognizing that this is a unique space is the beginning of the conversation. Ravi Madan: Yeah, and I want to thank JCO for giving us this forum and the opportunity to publish these results and all the expert prostate cancer investigators who were part of this committee. We produced some good thoughts for the future. Davide Soldato: We appreciate you sharing more on your JCO article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Olufunmilayo “Funmi” Olopade, director for the Center for Clinical Cancer Genetics and Global Health at the University of Chicago, credits her Nigerian upbringing for her focus on global cancer genetics.“My Yoruba culture really worships our ancestors and the people before us,” Olopade said on the Cancer History Project podcast. “And so that's why I was able to really say, ‘Okay, let's lay the foundation for genetics. Let's go to Nigeria.'”Olopade appears on this special Black History Month episode of the Cancer History Project Podcast in conversation with Robert A. Winn, director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center and guest editor for The Cancer Letter for Black History Month highlighting some of the giants in the field of cancer research.This episode is sponsored by City of Hope, the American Society of Clinical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center.Olopade is certainly a giant in cancer genetics and global health.“For those of you who don't know, Dr. Olopade is not only the director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago, but she is really a giant in the field and internationally renowned in the context of her expertise in breast cancer,” Winn said on the podcast. “By the way, for those of you who thought you knew Dr. Olopade, remember that she is a really rare, not only National Academy, but in that top 1% of 1% of the 2025 MacArthur Fellowship, also known as the Genius Grant.”On this episode of the Cancer History Project Podcast, Olopade shares her story of immigrating to the U.S. from Nigeria to pursue medicine, and finding her way to becoming a leading expert in oncology.“For us to honor Black History Month, we have to honor all the people who mentored us, who were ahead of us,” Olopade said. “For me, my father was a pastor, and my parents really wanted a doctor. I had big brothers and sisters, I was number 5 of 6 children, and there was just one last chance to find a doctor in the family. Because in those days, growing up in Nigeria, you were either a teacher or a pastor, or and then in his generation he became a pastor.”Growing up in Nigeria, Olopade was deeply influenced by the health disparities she saw due to lack of healthcare access, which initially sparked an interest in cardiology.Explore related articles and read the full transcript: https://cancerhistoryproject.com/article/funmi-olopade-podcast/ 

Tom opens this week's livestream with updates and announcements:Registration remains open for the New Biology Experience at Polyface Farm (June 2026). Tom reminds the audience there's still time to sign up and join him, the New Biology Clinic team, and community members for a weekend of talks, food, music, and connection.New Biology Experience link here.In honor of Heart Month, DrTomCowan.com is offering a Heart Health Sale on:Hibiscus Concentrate and Human Heart, Cosmic Heart book.This sale ends TONIGHT at 11:59 PM PT.This week's science news includes:-A satirical open letter to Vernon Coleman and the announcement of his nomination for the “Put-sky Gas Bag of the Year” award-A Johns Hopkins study linking hydrogen sulfide (fart gas) to Alzheimer's prevention-A claim that the shingles vaccine slows aging and dementia-Evolution “going into overdrive” exactly 66 million years ago-A new mRNA-based sickle cell “cure” priced at $3 millionA thoughtful Q&A on:-Are chemtrails real? And if so, how should we go about detoxifying from chemtrails?-Is it OK to blend foods?-Why do people get kidney stones and what can you do to prevent them?-What are warts and what is their purpose?-Is shedding real?-What about cataracts?-Somebody asked about getting a superficial fungal infection—usually in places like your groin or your armpit, or sometimes what's called athlete's foot.Support the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

When 84-year-old Nancy Guthrie disappeared from her home, investigators were quickly faced with blood evidence and ransom claims that did not align with standard abduction patterns. In this episode of Zone 7, Sheryl McCollum, retired NYPD homicide detectives Dan Murphy and Tom Smith, and forensic pathologist Dr. Priya Banerjee assess why blood at the scene, a prolonged presence inside the home, and Nancy’s medical vulnerabilities undermine the ransom narrative. The panel also examines investigative decisions and evidence handling that may shape accountability. For those looking to catch up further as the situation develops, additional coverage and updates can be found on Crime Stories with Nancy Grace. Highlights: • (0:00) Sheryl McCollum welcomes listeners, introduces the Nancy Guthrie case, and brings in Dan Murphy, Tom Smith, and Dr. Priya Banerjee • (1:30) Savannah Guthrie’s early silence and why not using her platform immediately raised concern • (2:15) Blood at the scene, smashed cameras, and why this should have been treated as an abduction from the start • (4:15) Interior crime scenes, early release, and how evidence integrity can be compromised • (4:45) Dr. Priya Banerjee on age, blood thinners, cardiac disease, and stress-related death • (7:15) The 41-minute timeline inside the home and why it defies kidnapping patterns • (8:30) Delayed ransom demands, media involvement, and why the timing doesn’t track • (12:15) Lights left on inside the house and behavior inconsistent with covert abduction • (13:30) Bitcoin ransom logic and why mixed-payment demands raise red flags • (14:15) A robbery-gone-wrong scenario and what happens if the victim recognizes the offenders • (16:15) Chronic pain, medication dependency, and why prolonged captivity is medically unlikely • (19:00) Family video statements, proof-of-life questions, and linguistics shifts investigators notice • (21:00) Reactionary law enforcement activity and repeated returns to the scene • (24:30) Pacemakers, Apple Watch connectivity, and what technology may still reveal • (28:30) Leadership optics, media interference, and the impact of active investigations • (36:45) Reward amounts, chain of custody concerns, and courtroom implications • (41:30) Final thoughts from the panel on recovery efforts, investigative outlook, accountability, and why Sheryl believes it was never about the money Guest Bio: Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Dan Murphy is a retired NYPD Detective-Sergeant with extensive experience in homicide, major case investigations, and counterterrorism. During his career, he served in units including the Major Case Squad and the FBI/NYPD Joint Terrorism Task Force. Since retiring from law enforcement, Dan has served as Chief Security officer for U.S. Bancorp, co-authored Workplace Safety: Establishing an Effective Violence Prevention Program, and co-hosts the podcast Gold Shields. Tom Smith is a retired NYPD detective and 2024 National Law Enforcement Hall of Fame inductee. Over 30 years of service, he worked in patrol, narcotics, and robbery investigations and spent 17 years working with the FBI/NYPD on the Joint Terrorism Task Force, including an overseas deployment to Afghanistan. Tom co-hosts the podcast Gold Shields, lectures on criminal justice and terrorism, and provides investigative commentary for national media outlets. Enjoying Zone 7? Leave a rating and review where you listen to podcasts. Your feedback helps others find the show and supports the mission to educate, engage, and inspire. Sheryl “Mac” McCollum is an active crime scene investigator for a Metro Atlanta Police Department and the director of the Cold Case Investigative Research Institute, which partners with colleges and universities nationwide. With more than 4 decades of experience, she has worked on thousands of cold cases using her investigative system, The Last 24/361, which integrates evidence, media, and advanced forensic testing. Her work on high-profile cases, including The Boston Strangler, Natalie Holloway, Tupac Shakur and the Moore’s Ford Bridge lynching, led to her Emmy Award for CSI: Atlanta and induction into the National Law Enforcement Hall of Fame in 2023. Social Links: • Email: coldcase2004@gmail.com • Twitter: @ColdCaseTips • Facebook: @sheryl.mccollum • Instagram: @officialzone7podcast Preorder Sheryl’s upcoming book, Swans Don’t Swim in a Sewer: Lessons in Life,Justice, and Joy from a Forensic Scientist, releasing May 2026 from Simon and Schuster. https://www.simonandschuster.com/books/Swans-Dont-Swim-in-a-Sewer/Sheryl-Mac-McCollum/9798895652824 See omnystudio.com/listener for privacy information.

In this episode of Preconceived, Zale explores the often misunderstood topic of infidelity, revealing why cheating is more common and psychologically complex than it appears on the surface. Joined by Dr. Dylan Selterman, a Johns Hopkins psychology professor, this discussion uncovers the motivations, psychological factors, and societal influences around cheating in relationships. Notably, the episode delves into the surprising revelation that many individuals do not regret cheating, examining the underlying psychological and emotional factors that contribute to this mindset.Learn more about Dylan Selterman at https://www.dylanselterman.com/ Hosted on Acast. See acast.com/privacy for more information.

In this episode of Med School Minutes, we sit down with Dr. Arthur Burnett, a Johns Hopkins urologist, researcher, and professor whose work helped unlock the science behind Viagra and reshape how medicine understands male sexual health.In recognition of Black History Month, we reflect on Dr. Burnett's groundbreaking career, his impact on men's health research, and the importance of representation and mentorship in medicine.From nitric oxide and vascular health to aging, prostate cancer, and longevity, this conversation explores how scientific discovery shapes both medicine and culture, and what future physicians should know.

Dr. Mehmet Oz, head of Medicare and Medicaid Services, is urging people to make sure they and their young children have gotten the measles vaccine. That follows an outbreak of as many as seven hundred cases nationwide this year. We speak with Dr. Patrick Mularoni, a pediatric emergency physician at Johns Hopkins All Children's Hospital, about vaccine hesitancy and additional precautions during this outbreak. See omnystudio.com/listener for privacy information.

In his weekly clinical update during Ground hog week, Dr. Griffin and Vincent Racaniello are back to discuss the measles outbreak in South Carolina, American Academy of Pediatrics vaccine recommendations and shingles vaccine and the reduction of dementia, then deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wastewater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, estimated effectiveness of this year's COVID-19 vaccine, long COVID treatment center, where to go for answers to your long COVID questions, long COVID in children, the potential benefits of metformin to reduce disease severity following SARS-CoV-2 infection in obese and overweight patients and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Grading the groundhogs (National Oceanic and Atmospheric Administration) Sand Mountain Sam predicts an early spring (News19) All About the AAP Recommended Immunization Schedule (healthychildren.org) Recommended Childhood and Adolescent Immunization Schedule: United States, 2026: Policy Statement (American Academy of Pediatrics: Pediatrics) Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments (LANCET: Neurology) Detection of avian flu antibodies in Dutch dairy cow: ECDC risk assessment remains unchanged (European Centre for Disease Prevention and Control) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard(South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19 (JAMA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study (LANCET: Infectious Diseases) Long COVID is here to stay—even in children (LANCET: Infectious Diseases) Early administration of neutralising monoclonal antibodies and post-acute sequelae of COVID-19 (International Journal of Infectious Diseases) Preventing Long COVID With Metformin (CID) Metformin may reduce risk of long COVID by 64% in overweight or obese adults (CIDRAP) Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese (CID) Preventing Long COVID With Metformin (CID) New review highlights growing evidence that diabetes drug metformin can prevent long COVID (CIDRAP) Reaching out to US house representative Letters read on TWiV 1294 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psilocybin Study for Religious Leaders in 2016. The epiphanies he had at Hopkins forever changed the trajectory of his work and led him to start Ligare in 2021. In this conversation, Hunt Priest reflects on how participating in the Johns Hopkins study reshaped his understanding of Christianity, embodiment, and spiritual experience. Drawing on his background as an Episcopal priest, he explores the deep resonance between psychedelic experiences and Christianity, arguing that non-ordinary states of consciousness have always been central to religious life, even if institutional churches have often marginalized them. The discussion ranges from spiritual emergence and theological disruption to healing, discernment, and the role clergy can play in preparation and integration. Hunt also shares his own profound embodied experience during the study where he encountered Vedic and Upanishadic concepts firsthand. He explains how it ultimately led him to found Ligare, a Christian psychedelic society aimed at bridging psychedelics, healing, and the Christian mystical tradition.   In this episode, you'll hear: Hunt's ideas of how psychedelic experiences connect with Christian sacraments and liturgical practices How psychedelics connect with understandings of religious pluralism and the diversity of spiritual experiences Resources for working through ideas that psychedelic experiences could be sinful or demonic Hunt's thoughts on navigating theological disruption, spiritual emergence, and expanded images of God Why embodiment and bodily wisdom are central to spiritual insight and healing The vital opportunity institutional religion risks missing in the current psychedelic renaissance   Quotes: "I think there's a lot of us [clergy] out there that understand that the spiritual issues that come up with psychedelics are important and need to be tended to in a sensitive way—in an open minded way, an open hearted way." [14:36] "The Church has, over time, taught people to not trust their minds or their bodies. And that's a huge mistake because our bodies keep the score and they also are one of the places we hold wisdom—which was the biggest lesson I got from the first experience I had at Hopkins." [17:39] "That's why the spiritual care professionals could be so important: when these issues, these spirit big spiritual questions or even a collapse of your own theological framework happens, you need help to put it back together. And just like therapy helps us put our emotional life back together, I think a good spiritual director or spiritual advisor—one-on-one or small group work—can help us put our theology back together." [21:47]   Links: Ligare website Ligare on Instagram Hunt on Instagram Hunt on LinkedIn Center for Action and Contemplation website Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD Psychedelic Medicine Association Porangui  

"Without our health, we don't have anything." Join host Heather in this deeply personal and enlightening episode of Health, Harmony and Heather as she sits down with Jim Curtis—author, motivational speaker, and health tech innovator. Jim shares his harrowing and inspiring journey of battling a mysterious, undiagnosed chronic illness 20 years ago that eventually left him in a wheelchair. From searching for answers at Johns Hopkins to learning from Kung Fu masters and shamans, Jim discusses how he moved past despair and pain to reverse his condition through a shift in mindset and functional medicine. In this episode, we explore: The "Anti-Inflammatory Mindset": How mental inflammation can be more destructive than physical inflammation. The Stimulati Experience: Discovering the "stimuli"—the extraordinary people and minds that ignite our passion and propel us toward healing. Bio-Individuality: Why there is no "silver bullet" and how to find the specific diet and lifestyle hacks (from cold therapy to grounding) that work for your unique DNA. Navigating Big Food & Pharma: Understanding how marketing impacts our health and why we must become advocates who "question our doctors". The Power of Breath: Practical tips on nasal breathing and the "box breathing" technique to lower stress and oxygenate your body. Whether you are dealing with a health setback or simply looking to "crowd out" bad habits with better ones, this conversation provides a roadmap for taking your life into your own hands. Book: The Stimulati Experience: 9 Skills for Getting Past Pain, Setbacks and Trauma to Ignite Health and Happiness Instagram: @JimCurtis1 Health, Harmony and Heather is dedicated to enriching life perspectives by exploring social phenomena, the human condition, and our connection to ourselves and the planet. We dive into physical, mental, and spiritual health to help you find your innermost truth, happiness, and freedom. Website: ⁠www.heatherthomson.com⁠ You Tube: ⁠https://youtube.com/@iamheathert?si=ZvI9l0bhLfTR-qdo⁠ Inquiries about this podcast: ⁠Karin@sireniamedia.com⁠ Social media:  IG: ⁠https://www.instagram.com/iamheathert/⁠ #HealthAndHarmony #JimCurtis #FunctionalMedicine #ChronicPainRecovery #Biohacking #IntegrativeNutrition #MindsetShift   Learn more about your ad choices. Visit megaphone.fm/adchoices

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Diane Hennacy, M.D. is a Johns Hopkins-trained neuropsychiatrist and neuroscientist, former Harvard faculty member, and an award-winning author and clinician. She began studying autism in 1987, when she spent six months with Sir Michael Rutter at the Institute for Psychiatry in London. Her decades long research focused on investigating reports of telepathy and precognition in autistic children was the inspiration for The Telepathy Tapes. SPONSORS https://mizzenandmain.com - Use code DANNY20 for 20% off your first order. https://prizepicks.onelink.me/LME0/DANNY - Use code DANNY & get $50 in lineups when you play your first $5 lineup! https://amentara.com/go/DJ - Use code DJ22 for 22% off your first order. https://shopmando.com - Use code DANNY for 20% off + free shipping. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://drdianehennacy.com https://hennacyinstitute.org FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTILNE 00:00 - How a Johns Hopkins trained psychiatrist got into ESP 04:46 - Savant Syndrome 06:48 - Why psychiatry disagrees with parapsychology 07:20 - Working down the hall from John Mack 11:28 - Why Diane wanted to be a neurosurgeon 16:34 - Where memory is stored in the brain 18:42 - Hippocampus' role in memory & ESP 25:51 - How oxygen deprivation destroys memory 30:49 - Harmful brain effects of breath-holding 32:14 - Effects of ketogenic state on the brain 35:25 - The autism & telepathy connection 39:44 - Savant Syndrome in blind & autistic individuals 45:51 - Neuroscience is a flawed model 51:06 - The analytical couch & the root of psychiatry 57:45 - How to prove or disprove ESP phenomena 01:01:57 - 97% accuracy telepathy test 01:11:21 - Possible materialist explanation for autistic ESP 01:16:25 - Why autistic individuals are more likely to experience ESP 01:25:25 - The problems with memory 01:26:50 - People who can't forget anything (hyperthymesia) 01:30:41 - White matter in the brain 01:34:48 - Microtubules & consciousness 01:40:53 - How to advance microtubule research 01:43:00 - Ultrasound as Alzheimer's therapy 01:45:30 - Applications of infrared light therapy 01:54:12 - The body's internal "fiber optic" system 01:58:21 - Human's natural telepathic abilities have atrophied over time 02:01:17 - Schools are failing our youth 02:05:13 - Ancient humans' telepathic abilities 02:09:45 - How the bible warns against the written word 02:15:09 - Autistic telepathic kids who mention bible characters 02:19:43 - The sixth sense humans have buried inside them 02:24:02 - The hidden superpowers of the nose 02:28:36 - How your nose can smell true love 02:32:23 - The new split in human evolution 02:35:32 - Proof of technologically advanced ancient humans 02:40:59 - The filter hypothesis 02:48:10 - Disproving the materialist model 02:51:38 - Non-autistic people with ESP 02:54:20 - Autistic people who see dead people Learn more about your ad choices. Visit podcastchoices.com/adchoices

Brain organoids, cell collections grown in a lab to study diseases like Alzheimer's, have created excitement because they are a bit more representative of a real brain. Johns Hopkins cell engineering expert Vasiliki Machairaki says there is another technique underway … What is an assembloid? Elizabeth Tracey reports Read More »

Stem cells used to be derived from human embryos, but not anymore. Now a simple blood test can allow stem cells to be induced from cells found there, says Johns Hopkins cell engineering expert Vasiliki Machairaki. Machairaki: Induced pluripotent stem … How do stem cells derived from blood differ from those from embryos? Elizabeth Tracey reports Read More »

A simple blood test may soon help precisely identify your risk for Alzheimer's disease by inducing some of your cells to go back in time, looking like they did when you were an embryo. Johns Hopkins cell engineering expert Vasiliki … What might reprogramming cells have to do with understanding Alzheimer's? Elizabeth Tracey reports Read More »

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss with disgust the decline and fall of American public health and the rise of "only me" when highlighting completion of the US withdrawal from the WHO and possibility of making IPV and MMR optional vaccines, before Dr. Griffin then deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, Europe losing its measles elimination status, first measles death in Mexico, almost 1000 measles cases in South Carolina, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, the effectiveness of this season's influenza vaccine, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode US completes withdrawal from World Health Organization (AP News) Rejecting Decades of Science, Vaccine Panel Chair Says Polio and Other Shots Should Be Optional (NY Times) A Frightening Interview (Beyond the Noise) Unexplained Pauses in Centers for Disease Control and Prevention Surveillance: Erosion of the Public Evidence Base for Health Policy (Annals of Internal Medicine) Wastewater for measles (WasterWater Scan) UK among 6 European countries losing measles elimination status (Dougall MD: DG Alerts) European Regional Verification Commission for Measles and Rubella Elimination (RVC) (WHO: Europe) Measles Outbreak Associated with an Infectious Traveler — Colorado, May–June 2025 (CDC: MMWR) South Carolina measles cases hit 789, surpassing Texas' 2025 outbreak total (Reuters) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) States across the country report first measles cases of year(CIDRAP) First measles death confirmed in Mexico in 2026 (Mexico News) Influenza: Waste water scan for 11  pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza Vaccine Effectiveness Among Children With and Without Underlying Conditions(Pediatrics) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Effectiveness and Durability of the BNT162b2 KP.2 vaccine against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults (OFID) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients (BMC Infectious Diseases) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1292 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

We don't need to hide.Our guest this week shares this message loud and clear: as providers, we have nothing to hide from our patients.Dr. Erica Urquhart knows a thing or two about our healthcare system - having trained at Harvard as a biomedical engineer, she received a MD-PhD in Molecular and Neuroscience from Johns Hopkins and is now a practising orthopedic surgeon.She joins today to talk through her outlook on a broken system, as told in her upcoming book ‘Invisible Hand Wielding the Scalpel: Paying the Price in America's Fractured Healthcare System'.—We spoke about the value of transparency in healthcare, her constant battle with massive insurance companies, the capitalist emphasis in the system, the influence of commercial insurers in driving the cost and accessibility of care, and the fundamental importance of sickness prevention.Follow me on Instagram and Facebook @ericfethkemd and checkout my website at www.EricFethkeMD.com. My brand new book, The Privilege of Caring, is out now on Amazon! https://www.amazon.com/dp/B0CP6H6QN4

What if psychedelics could transform the way we treat trauma, chronic pain, and insomnia? This week, neuroscientist and psychedelic researcher Grace Blest-Hopley joins the show to break down the research on psychedelics and female biology. She discusses how psychedelics work in the brain, and the ways that psychedelic-assisted therapies might be beneficial for women in midlife. Links to resources mentioned in this episode: Hystelica’s resources on psychedelic retreats The Heroic Hearts Project Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings The acute effects of classic psychedelics on memory in humans Psilocybin with psychological support for treatment-resistant depression: six-month follow-up Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Johns Hopkins study on psychedelics and Alzheimer’s Note: In this show, we use “women” as shorthand for people with XX chromosomes. We understand sex and gender are more complex, and acknowledge the experiences we describe reach beyond that word.See omnystudio.com/listener for privacy information.

On this week’s episode, we’re continuing our Guidelines Series exploring the 2022 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. If you missed our first episode in the series, give it a listen to hear about the most recent recommendations regarding Pulmonary Hypertension definitions, screening, and diagnostics. Today, we’re talking about the next steps after diagnosis. Specifically, we’ll be discussing risk stratification, establishing treatment goals, and metrics for re-evaluation. We’ll additionally introduce the mainstays of pharmacologic therapy for Pulmonary Hypertension. Meet Our Co-Hosts Rupali Sood  grew up in Las Vegas, Nevada and made her way over to Baltimore for medical school at Johns Hopkins. She then completed her internal medicine residency training at Massachusetts General Hospital before returning back to Johns Hopkins, where she is currently a pulmonary and critical care medicine fellow. Rupali’s interests include interstitial lung disease, particularly as related to oncologic drugs, and bedside medical education. Tom Di Vitantonio  is originally from New Jersey and attended medical school at Rutgers, New Jersey Medical School in Newark. He then completed his internal medicine residency at Weill Cornell, where he also served as a chief resident. He currently is a pulmonary and critical care medicine fellow at Johns Hopkins, and he’s passionate about caring for critically ill patients, how we approach the management of pulmonary embolism, and also about medical education of trainees to help them be more confident and patient centered. Key Learning Points 1) Episode Roadmap How to set treatment goals, assess symptom burden, and risk-stratify patients with suspected/confirmed pulmonary arterial hypertension (PAH). What tools to use to re-evaluate patients on treatment Intro to major PAH medication classes and how they map to pathways. 2) Case-based diagnostic reasoning Patient: 37-year-old woman with exertional dyspnea, mild edema, abnormal echo, telangiectasias + epistaxis → raises suspicion for HHT (hereditary hemorrhagic telangiectasia) and/or early connective tissue disease. Key reasoning move: start broad (Groups 2–5) and narrow using history/exam/testing. In a young patient without obvious left heart or lung disease, think more about Group 1 PAH (idiopathic/heritable/associated). HHT teaching point: HHT can cause PH in more than one way: More common: high-output PH from AVMs (often hepatic/pulmonary) Rare (1–2% mentioned): true PAH phenotype (vascular remodeling; associated with ALK1 in some patients), behaving like Group 1 PAH. 3) Functional class assessment WHO Functional Class: Class I: no symptoms with ordinary activity, only with exertion Class II: symptoms with ordinary activity Class III: symptoms with less-than-ordinary activity (can't do usual chores/shopping without dyspnea) Class IV: symptoms at rest Practical bedside tip they give: Ask if the patient can walk at their own pace or keep up with a similar-age peer/partner. If not, think Class II (or worse). 4) Risk stratification at diagnosis: why, how, and which tools Big principle: treatment choices are driven by risk, and the goal is to move patients to low-risk quickly. ESC/ERS approach at diagnosis (as described): Use a 3-strata model predicting 1-year mortality: Low: 20% ESC/ERS risk assessment variables (10 domains discussed): Clinical progression, signs of right heart failure, syncope WHO FC Biomarkers (NT-proBNP) Exercise capacity (6MWD) Hemodynamics Imaging (echo; sometimes cardiac MRI) CPET (peak VO₂; VE/VCO₂ slope) They note: even if you don't have everything, the calculator can still be useful with ≥3 variables. REVEAL 2.0: Builds on similar core variables but adds further patient context (demographics, renal function, BP, DLCO, etc.) Case result: both tools put her in intermediate risk (ESC/ERS ~1.6; REVEAL 2.0 score 8), underscoring that mild symptoms can still equal meaningful mortality risk. 5) Treatment goals and follow-up philosophy What they explicitly prioritize: Help patients feel better, live longer, and stay out of the hospital Use risk tools to communicate prognosis and to track improvement Reassess frequently (they mention ~every 3 months early on) until low risk is achieved “Time-to-low-risk” is an important treatment goal Also emphasized: The diagnosis is psychologically heavy; patients need clear counseling, reassurance about the plan, and connection to support groups. 6) Medication classes for the treatment of PAH Nitric oxide–cGMP pathway PDE5 inhibitors: sildenafil, tadalafil Soluble guanylate cyclase stimulator: riociguat Important safety point: don't combine PDE5 inhibitors with riociguat (risk of significant hypotension/hemodynamic effects) Endothelin receptor antagonists (ERAs) “-sentan” drugs: bosentan (less used due to side effects/interactions), ambrisentan, macitentan Teratogenicity emphasized Hepatotoxicity that requires LFT monitoring Can cause fluid retention and peripheral edema Prostacyclin pathway Prostacyclin analogs/agonists: Epoprostenol (potent; short half-life; IV administration) Treprostinil (IV/SubQ/oral/inhaled options) Selexipag (oral prostacyclin receptor agonist) 7) Sotatercept (post-guidelines) They note sotatercept wasn't in 2022 ESC/ERS but is now “a game changer” in practice: Mechanism: ligand trap affecting TGF-β signaling / remodeling biology Positioned as potentially more disease-modifying than pure vasodilators Still evolving: where to place it earlier vs later in regimens is an active question in the field 8) How risk category maps to initial treatment intensity General approach they outline: High risk at diagnosis: parenteral prostacyclin (IV/SubQ) strongly favored, often aggressive early Intermediate risk: at least dual oral therapy (typically PDE5i + ERA); escalate if not achieving low risk Low risk: at least one oral agent; many still use dual oral depending on etiology/trajectory For the case: intermediate-risk → start dual oral therapy (they mention tadalafil + ambrisentan as a typical choice), reassess in ~3 months; add a third agent (e.g., selexipag/prostacyclin pathway) if not low risk.  References and Further Reading Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. doi: 10.1093/eurheartj/ehad005. PMID: 36017548. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what’s old is new. F1000Res. 2019 Jun 19;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672; PMCID: PMC6584967. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc. 2023 Apr 18;12(8):e029024. doi: 10.1161/JAHA.122.029024. Epub 2023 Apr 7. PMID: 37026538; PMCID: PMC10227272. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID: 36877098. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. Erratum in: JAMA. 2022 Sep 6;328(9):892. doi: 10.1001/jama.2022.13696. PMID: 35412560.

Episode Summary: In this conversation, Kimberly and Josh Redd delve into the critical topic of inflammation, exploring its prevalence, symptoms, and the various health conditions it can exacerbate, including autoimmune diseases and fertility issues. They discuss the impact of diet, gut health, and environmental toxins on inflammation, as well as the promising role of stem cell therapy in managing chronic inflammatory conditions. The conversation emphasizes the importance of education and proactive health management, encouraging listeners to take control of their health through informed lifestyle choices.Chapters00:00 The Rise of Inflammation Awareness03:04 Understanding Inflammation Symptoms05:59 Inflammation's Impact on Children09:00 Autoimmunity and Inflammation12:02 Dietary Influences on Inflammation14:51 The Role of Gut Health17:59 Environmental Toxins and Inflammation21:30 Big Picture Health Strategies23:53 Cooking and Nutrition Control25:25 Understanding Stem Cell Therapy28:56 Stem Cells and Inflammation31:55 Innovations in Stem Cell Treatments34:19 Insurance and Accessibility of TreatmentsSponsors: FATTY15 OFFER: Fatty15 is on a mission to replenish your C15 levels and restore your long-term health. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/KIMBERLY and using code KIMBERLY at checkout.USE LINK: fatty15.com/KIMBERLYDr. Josh Redd Resources: Book: THE 30-DAY INFLAMMATORY RESET: A Complete Guide to Healing Your Immune System Website: DrJoshRedd.com Tik Tok: drjoshred Instagram: @drjoshredd Bio: Dr. Josh Redd, NMD, MS, MPHb, is an industry leader in functional and personalized medicine. With over 12 years of post-graduate education—including two master's degrees and two doctorate degrees—he brings an unmatched depth of training and experience to his patients. His expertise in regenerative medicine includes over 1,000 precision-guided injections for spinal, joint, and soft tissue treatment, helping athletes and active individuals optimize performance and accelerate recovery. He holds an MS in Human Nutrition and Functional Medicine, an MPHb from Johns Hopkins (with an emphasis on molecular biology and immunology), and a Doctor of Chiropractic from Parker University. Most recently, he graduated from naturopathic medical school and completed his residency in regenerative medicine and stem cell injections through Bastyr University.Dr. Redd is the founder of RedRiver Health & Wellness, one of the largest functional medicine clinics in the U.S., with eight locations across Utah, New Mexico, Nevada, and Idaho, and PalmaVita Clinic, a regenerative medicine and athletic performance center in Spanish Fork, Utah.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss screwworm, how the shingles vaccination slows biological aging (for all of you who want to reset 'the clock' and live forever…..you know who you are Musk, Bezos) and getting one dose of the HPV vaccine, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how losing our elimination status is the cost of doing business (going for broke is never a good business model !) where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, the effectiveness of this season's influenza vaccine, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode New World Screwworm: Outbreak Moves into Northern Mexico……with an official tag "This is an official CDC Health Advisory" (CDC: Health Alert Network) Association between shingles vaccination andslower biological aging: Evidence from a U.S. population-based cohort study (The Journals of Gerontology series A) Noninferiority of One HPV Vaccine Dose to Two Doses (NEJM) Herd effect of human papillomavirus vaccination on incidence of high-grade cervical lesions: (LANCET: Public Health) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) Detections of Highly Pathogenic Avian Influenza in Wild Birds (USDA: Animal and Plant Health Inspection Service) Delaware, Georgia see major commercial avian flu outbreaks (CIDRAP) Wastewater for measles (WasterWater Scan) Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 (CDC: MMWR) Notes from the Field: Retrospective Analysis of Wild-Type Measles Virus in Wastewater During a Measles Outbreak — Oregon, March 24–September 22, 2024 (CDC: MMWR) Measles cases and outbreaks (CDC Rubeola) Measles vaccine recommendations from NYP (jpg) Tracking Measles Cases in the U.S. (Johns Hopkins) Utah measles total rises to 216; CDC deputy director says losing elimination status'cost of doing business' (CIDRAP) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Assessing MMR vaccination coverage gaps in US children with digital participatory surveillance (Nature Health) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies (CMI: Clinical Microbiology and Infection) Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026 (Eurosurveillance) Moderate protection from vaccination against influenza A(H3N2) subclade K in Beijing, China, September to December 2025 (Eurosurviellance) Current flu vaccine provides moderate protection against severe disease, interim analyses suggest (CIDRAP) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virusnfection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1290 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

The medical system expects you to chase 33 different screening appointments across multiple specialists and check your organs one at a time. But there's a smarter way that scans your entire body in under an hour to catch cancer, aneurysms, fatty liver, and other serious health issues before they become life-threatening. In today's episode, I sit down with Dr. Daniel Durand, Chief Medical Officer of Prenuvo, to talk about the real-world power (and limitations) of proactive whole-body MRI screening. Dr. Durand walks us through how this advanced screening method detects over 500 conditions, many of which traditional screenings miss. We talk about the importance of early detection for cancers and neurodegenerative diseases, and how this proactive approach to health can save lives.   "It's better to see things early when you can intervene, and see them in a controlled context when you're healthy." ~ Dr. Daniel Durand   In This Episode: -  Introduction to Dr. Daniel Durand and his background - Conventional vs whole body scans - Conditions that whole-body MRI can detect - Bringing scans to underserved populations - Imaging for risk identification vs. diagnosis - How often you should rescan and what to expect - EMF exposure concerns and MRI safety parameters - How consumer demand is driving change in medicine   Products & Resources Mentioned: Prenuvo Whole-Body MRI: My listeners get a special discount when you book at https://prenuvo.com/wendymyers  Bon Charge Blue Light Blockers: Get 15% off with code WENDY at https://boncharge.com  Organifi Happy Drops: Save 20% with code MYERSDETOX at https://organifi.com/myersdetox  Organifi Collagen: Use code MYERSDETOX for 20% off at https://organifi.com/myersdetox  Chef's Foundry P600 Ceramic Cookware: Get 20% off with code WENDY20 at https://chefsfoundry.com  Heavy Metals Quiz: Take it for free at https://heavymetalsquiz.com    About Dr. Daniel Durand: Dr. Daniel Durand is a dual board-certified adult & pediatric radiologist and Chief Medical Officer at Prenuvo, where he leads clinical operations, research, and the medical group for the world's largest network of proactive whole-body MRI clinics. Previously, he served as Chief Clinical Officer & Chief Innovation Officer at LifeBridge Health and held leadership roles in accountable care at Johns Hopkins. He is passionate about empowering primary care and shifting medicine toward true prevention through advanced imaging. Learn more at: https://prenuvo.com/wendymyers    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.